The heart is a never-stopping engine that relies on a formidable pool of mitochondria to generate energy and propel pumping. Because dying cardiomyocytes cannot be replaced, this high metabolic rate ...

Abstract In photosynthetic reaction centers from purple bacteria (PbRCs) from Rhodobacter sphaeroides, the secondary quinone Q B accepts two electrons and two protons via electron-coupled proton ...

This work also demonstrates a new strategy for developing synthetic metabolic pathways: recruiting non-natural biochemical reactions enabled by computationally designed enzymes.

Objectives Gut microbiota is a key component in obesity and type 2 diabetes, yet mechanisms and metabolites central to this interaction remain unclear. We examined the human gut microbiome’s ...

Metabolic pathways refer to the continuous chemical reactions in the metabolic process in vivo. Compounds are the major participant for most metabolic pathways. It is essential to determine which ...

For the principal metabolism pathway of melatonin, there are intriguing questions, for example, related to the products that are favored, namely N -acetyl-5-hydroxytryptamine or 6-hydroxymelatonin, ...

Furthermore, these changes in metabolism may even override signals inducing vessel sprouting. Here, we review how EC metabolism differs between the normal and dysfunctional/diseased vasculature and ...

Application of native chemical ligation logic to the case of an N-terminal proline is described. Two approaches were studied. One involved incorporation of a 3R-substituted thiyl-proline derivative.

Eolo Pharma plans to initiate Phase 2 clinical trials in 2025 to evaluate SANA’s long-term safety and efficacy as both a standalone and combination therapy for metabolic disease.

About Eolo Pharma Eolo Pharma is a clinical-stage biotechnology company advancing first-in-class small molecule therapies for obesity and metabolic disease. The company’s research focuses on targeting ...